Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$674.14M+55.02%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pablo Legorreta
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 100
- Beta
- 0.43
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.13
Financials
Revenue
$674.14M+55.0%Net Income
$17.88M-95.1%EBITDA
$176.40M-62.5%Free Cash Flow
$686.15M+58.5%EPS (diluted)
$0.04-96.2%Shares Outstanding (diluted)
556.90M+57.2%Operating Expenses
$259.74MCash & Debt
$836.99MReturn of Capital
$149.56MRevenue by Segment (annual)
$2.38BDividend per Share
$0.23Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.38B | $770.95M | $2.33 |
| 2024 | $2.26B | $858.98M | $1.92 |
| 2023 | $2.35B | $1.13B | $3.41 |
| 2022 | $2.24B | $42.83M | $0.10 |
| 2021 | $2.29B | $619.73M | $1.49 |
| 2020 | $2.12B | $975.04M | $1.28 |
| 2019 | $1.81B | $2.35B | $6.63 |
| 2018 | $1.79B | $1.38B | $3.89 |
| 2017 | $1.60B | $1.21B | $3.42 |
| 2016 | $1.88B | $565.91M | $0.93 |
| 2015 | $1.65B | $581.43M | $0.96 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RPRX's reported EPS growth of 9.3% a year over 10 years.
- EPS in 5 years
- $2.78
- Implied price
- $47.34
- Return from $57.16
- -3.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.54 — -58.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 14 | 17 | 20 | 23 |
|---|---|---|---|---|---|
| -0.7% | -19.8% | -15.8% | -12.5% | -9.6% | -7.1% |
| 4.3% | -15.8% | -11.6% | -8.1% | -5.1% | -2.4% |
| 9.3% | -11.7% | -7.4% | -3.7% | -0.5% | 2.3% |
| 14.3% | -7.7% | -3.1% | 0.7% | 4.0% | 7.0% |
| 19.3% | -3.7% | 1.1% | 5.1% | 8.6% | 11.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (15)
- Newsmarketbeat.com·11d ago·Neutral
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - PodcastAll In·17d ago·Neutral
Silicon Valley, Royalty, Legendary Investor, Bill Gerley. Tracker could's incredible. The legend who backed Uber and Zillow, who's lived through every major text cycle for over 25 years. You're not just a commentator, right? You've been an operator. I'd love to unlock this latent human potential. There's been no time in the history of the world where you can learn faster. You can increase your surface area for luck. I'm not a big fan of these dystopian narrative. The thing to do right now is to
View source ↗ - News (RSS)businessinsider·20d ago·Neutral
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration Program (TAP), a collaborative...
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and han…
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·25d ago·Neutral
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Royalty Pharma to present at upcoming investor conferences NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
View source ↗ - News (RSS)investing·31d ago·Neutral
Royalty Pharma expects modest return despite pelacarsen trial failure
View source ↗ - News (RSS)seekingalpha·31d ago·Neutral
Royal Gold: Royalty Play With Strong Growth Profile But No Longer Cheap
View source ↗ - News (RSS)yahoo·40d ago·Neutral
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and increased scalability for higher-value transactions. The company is capitalizing on inflows into the biopharma sector, with a strategic shift toward development-stage assets that yield higher IRRs and a strong track record of regulatory approvals. Several positive catalysts are coming up. All are poised to drive incremental …
View source ↗ - News (Marketaux)insidermonkey.com·53d ago·Positive
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? A prime example unfolded when Royalt[+334 characters]
View source ↗ - Newszacks.com·53d ago·Positive
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $1.18 per share
Typical surprise +11.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$1.32 vs $1.27beat
- Wed, May 6$1.30 vs $1.21beat
- Wed, Feb 11$1.46 vs $1.29beat
- Wed, Nov 5$1.17 vs $0.99beat
- Wed, Aug 6$1.14 vs $1.03beat
- Thu, May 8$1.06 vs $0.95beat
Estimates and results for RPRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RPRX officers and directors.
- Bought
- —
- Sold
- $85.2m
0 trades
69 trades
- Urist Marshallsold
- Hite Christophersold
- Hite Christophersold
- Hite Christophersold
- Coyne Terrance P.sold
- Coyne Terrance P.sold
- Urist Marshallsold
- Urist Marshallsold
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RPRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.